Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906)
K Kato, K Muro, K Minashi, A Ohtsu, S Ishikura… - International Journal of …, 2011 - Elsevier
PURPOSE: In this Phase II study, we evaluated the efficacy and toxicity of chemoradiotherapy
(CRT) with cisplatin (CDDP) and 5-fluorouracil (5-FU) for Stage II–III esophageal …
(CRT) with cisplatin (CDDP) and 5-fluorouracil (5-FU) for Stage II–III esophageal …
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3 …
K Kato, BC Cho, M Takahashi, M Okada, CY Lin… - The Lancet …, 2019 - thelancet.com
Background Chemotherapy for patients with advanced oesophageal squamous cell carcinoma
offers poor long-term survival prospects. We report the final analysis from our study of the …
offers poor long-term survival prospects. We report the final analysis from our study of the …
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer
K Kato, K Chin, T Yoshikawa, K Yamaguchi… - Investigational new …, 2012 - Springer
Purpose NK105 is a new drug delivery system formulation for paclitaxel (PTX) whose
recommended dose (RD) is 150 mg PTX equivalent/m 2 administered every 3 weeks, as …
recommended dose (RD) is 150 mg PTX equivalent/m 2 administered every 3 weeks, as …
Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer
…, K Furuta, T Matsuda, S Fujita, K Kato… - Cancer …, 2010 - Wiley Online Library
Adipocytokines are adipocyte‐secreted hormones associated with some malignancies such
as colorectal, breast, and prostate cancer. We hypothesized that changes in the levels of …
as colorectal, breast, and prostate cancer. We hypothesized that changes in the levels of …
[HTML][HTML] Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma
Y Doki, JA Ajani, K Kato, J Xu, L Wyrwicz… - … England Journal of …, 2022 - Mass Medical Soc
Background First-line chemotherapy for advanced esophageal squamous-cell carcinoma
results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival …
results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival …
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO …
Background Patients with advanced gastric or gastro-oesophageal junction cancer refractory
to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, …
to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, …
Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
…, SB Kim, SH Lee, J Bennouna, K Kato… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited
treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, …
treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, …
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro …
…, S Sakuramoto, IJ Chung, K Yamaguchi, K Kato… - The Lancet …, 2022 - thelancet.com
Background The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been reported. …
inhibitors in combination with oxaliplatin-based chemotherapy has previously been reported. …
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label …
…, T Tamura, N Sugimoto, H Cho, Y Omuro, K Kato… - The Lancet, 2018 - thelancet.com
Background Patients with advanced gastric or gastro-oesophageal junction cancer that
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo …
…, A Tsuji, VC Oliden, Q Liu, S Shah, P Bhagia, K Kato - The Lancet, 2021 - thelancet.com
Background First-line therapy for advanced oesophageal cancer is currently limited to
fluoropyrimidine plus platinum-based chemotherapy. We aimed to evaluate the antitumour activity …
fluoropyrimidine plus platinum-based chemotherapy. We aimed to evaluate the antitumour activity …